Online inquiry

IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14629MR)

This product GTTS-WQ14629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016941.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10683
UniProt ID Q9NYJ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14629MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10071MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ13737MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ11224MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ3822MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ3651MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ5081MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ11504MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ8982MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW